Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Authors
Keywords
-
Journal
GUT
Volume 66, Issue 1, Pages 168-179
Publisher
BMJ
Online
2016-11-04
DOI
10.1136/gutjnl-2016-312539
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex
- (2016) Giovanna Zinzalla CHEMBIOCHEM
- Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment
- (2016) Yinshi Huang et al. CLINICAL CANCER RESEARCH
- CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer
- (2016) Mark L. McCleland et al. JOURNAL OF CLINICAL INVESTIGATION
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer
- (2016) Domenico Ciliberto et al. PANCREATOLOGY
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- The Bromodomain: A New Target in Emerging Epigenetic Medicine
- (2015) Steven G. Smith et al. ACS Chemical Biology
- Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity
- (2015) S. K. Singh et al. EMBO JOURNAL
- ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
- (2015) S. Meidhof et al. EMBO Molecular Medicine
- Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation
- (2015) Nilotpal Roy et al. GENES & DEVELOPMENT
- EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
- (2015) Christine M. Fillmore et al. NATURE
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Acetylation site specificities of lysine deacetylase inhibitors in human cells
- (2015) Christian Schölz et al. NATURE BIOTECHNOLOGY
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- (2015) Pawel K Mazur et al. NATURE MEDICINE
- SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
- (2015) Kimberly H Kim et al. NATURE MEDICINE
- MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies
- (2015) E Hessmann et al. ONCOGENE
- The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
- (2015) P L Garcia et al. ONCOGENE
- Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition
- (2015) Katrin Liffers et al. Targeted Oncology
- SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin
- (2015) Seong Joon Park et al. TUMOR BIOLOGY
- Targeting BET bromodomains for cancer treatment
- (2015) Marie Jung et al. Epigenomics
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
- (2015) Celeste B. Greer et al. Cell Reports
- Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
- (2014) M. Tassara et al. BLOOD
- EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
- (2014) Bryson W Katona et al. CANCER BIOLOGY & THERAPY
- Disrupting the Interaction of BRD4 with Diacetylated Twist Suppresses Tumorigenesis in Basal-like Breast Cancer
- (2014) Jian Shi et al. CANCER CELL
- Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells
- (2014) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
- (2014) Junwei Shi et al. MOLECULAR CELL
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenetics and pancreatic cancer: Pathophysiology and novel treatment aspects
- (2014) Daniel Neureiter WORLD JOURNAL OF GASTROENTEROLOGY
- Driver mutations of cancer epigenomes
- (2014) David M. Roy et al. Protein & Cell
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
- (2013) Bjoern Chapuy et al. CANCER CELL
- Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS
- (2013) Takashi Yoshioka et al. GYNECOLOGIC ONCOLOGY
- A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
- (2012) K Mross et al. BRITISH JOURNAL OF CANCER
- A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
- (2012) U. Banerji et al. CLINICAL CANCER RESEARCH
- Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib
- (2012) Anja Lachenmayer et al. JOURNAL OF HEPATOLOGY
- Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
- (2012) A. Avan et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
- (2011) Georg Feldmann et al. CANCER BIOLOGY & THERAPY
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
- (2010) Masashi Kanai et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma
- (2010) Adam D. Toll et al. HUMAN PATHOLOGY
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
- (2010) Ron Epelbaum et al. NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
- Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells
- (2009) R P Sahu et al. BRITISH JOURNAL OF CANCER
- Biomarkers for predicting clinical responses to HDAC inhibitors
- (2009) Lindsay Stimson et al. CANCER LETTERS
- Isoform-specific histone deacetylase inhibitors: The next step?
- (2009) Sriram Balasubramanian et al. CANCER LETTERS
- E-Cadherin Regulates Metastasis of Pancreatic Cancer In Vivo and Is Suppressed by a SNAIL/HDAC1/HDAC2 Repressor Complex
- (2009) Johannes von Burstin et al. GASTROENTEROLOGY
- NFAT-Induced Histone Acetylation Relay Switch Promotes c-Myc-Dependent Growth in Pancreatic Cancer Cells
- (2009) Alexander Köenig et al. GASTROENTEROLOGY
- EP300-A miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas
- (2009) Soeren Torge Mees et al. INTERNATIONAL JOURNAL OF CANCER
- Role of the polycomb protein EED in the propagation of repressive histone marks
- (2009) Raphael Margueron et al. NATURE
- Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2
- (2008) A. V. Ougolkov et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer
- (2008) N. Dhillon et al. CLINICAL CANCER RESEARCH
- The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research
- (2008) Gwen Lomberk et al. CURRENT OPINION IN GASTROENTEROLOGY
- Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors
- (2008) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
- (2008) S. Jones et al. SCIENCE
- Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors
- (2008) Martin Haefner et al. WORLD JOURNAL OF GASTROENTEROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now